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Efficacy and Safety of Pioglitazone 
Monotherapy in Type 2 Diabetes 
Mellitus: A Systematic Review 
and Meta-Analysis of Randomised 
Controlled Trials
Fahmida Alam1, Md. Asiful Islam  2, Mafauzy Mohamed3, Imran Ahmad4, 
Mohammad Amjad Kamal5,6,7, Richard Donnelly8, Iskandar Idris8 & Siew Hua Gan9
Pioglitazone, the only thiazolidinedione drug in clinical practice is under scrutiny due to reported 
adverse effects, it’s unique insulin sensitising action provides rationale to remain as a therapeutic 
option for managing type 2 diabetes mellitus (T2DM). We conducted a systematic review and meta-
analysis comparing pioglitazone monotherapy with monotherapies of other oral antidiabetic drugs for 
assessing its efficacy and safety in T2DM patients. Mean changes in glycated haemoglobin (HbA1c), 
and mean changes in fasting blood sugar (FBS) level, body weight (BW) and homeostasis model 
assessment-insulin resistance (HOMA-IR) were primary and secondary outcomes, respectively. Safety 
outcomes were changes in lipid parameters, blood pressure and incidences of adverse events. Metafor 
package of R software and RevMan software based on random-effects model were used for analyses. 
We included 16 randomised controlled trials. Pioglitazone monotherapy showed equivalent efficacy as 
comparators in reducing HbA1c by 0.05% (95% CI: −0.21 to 0.11) and greater efficacy in reducing FBS 
level by 0.24 mmol/l (95% CI: −0.48 to −0.01). Pioglitazone showed similar efficacy as comparators in 
reducing HOMA-IR (WMD: 0.05, 95% CI: −0.49 to 0.59) and increasing high-density lipoprotein level 
(WMD: 0.02 mmol/l, 95% CI: −0.06 to 0.10). Improved blood pressure (WMD: −1.05 mmHg, 95% CI: 
−4.29 to 2.19) and triglycerides level (WMD: −0.71 mmol/l, 95% CI: −1.70 to 0.28) were also observed 
with pioglitazone monotherapy. There was a significant association of pioglitazone with increased BW 
(WMD: 2.06 kg, 95% CI: 1.11 to 3.01) and risk of oedema (RR: 2.21, 95% CI: 1.48 to 3.31), though the 
risk of hypoglycaemia was absolutely lower (RR: 0.51, 95% CI: 0.33 to 0.80). Meta-analysis supported 
pioglitazone as an effective treatment option for T2DM patients to ameliorate hyperglycaemia, adverse 
lipid metabolism and blood pressure. Pioglitazone is suggested to prescribe following individual 
patient’s needs. It can be a choice of drug for insulin resistant T2DM patients having dyslipidaemia, 
hypertension or history of cardiovascular disease.
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Type 2 diabetes mellitus (T2DM) is the most common chronic, metabolic disease whose prevalence is rapidly 
increasing worldwide. Insulin resistance (IR), the core metabolic defect contributes to the development of T2DM 
in approximately 92% of patients1. In IR condition, body cells mainly the peripheral adipose, muscle, and liver 
cells fail to respond properly to insulin signalling, resulting in decreased peripheral cells glucose uptake and 
increased hepatic glucose production2. Additionally, IR leads to impairment of insulin secretion by pancreatic 
β-cells. Hence, restoration of insulin sensitivity is the major treatment strategy for managing T2DM.
Thiazolidinediones (TZDs) are the only antidiabetic (AD) agents that function predominantly as insulin sen-
sitisers in peripheral and hepatic tissues by binding to and activating nuclear peroxisome proliferator-activated 
receptor γ (PPARγ) expressed in those tissues. Among Food and Drug Administration (FDA) approved TZDs, 
troglitazone (Rezulin) was withdrawn from the market in 2000 due to severe hepatotoxicity whereas rosiglitazone 
(Avandia) has fallen out of favour owing to the controversy surrounding its cardiovascular (CV) safety3. Although 
FDA restricted the use of rosiglitazone in 2010, it later reversed the decision in 2013 after reanalysing the results 
of a multicentre randomised trial involving 4,447 T2DM patients where there was no reported increase in the 
incidence of myocardial infarction (MI) or CV death due to rosiglitazone4. However, restriction withdrawal on 
the rosiglitazone could not re-establish its previous reliability in clinical practice. Currently, pioglitazone (Actos) 
is the only available PPARγ agonist used for treating T2DM patients5.
Owing to IR, patients with T2DM are associated with a cluster of abnormalities such as dyslipidaemia, hyper-
tension, increased expression of inflammatory mediators, decreased plasma adiponectin level, hypercoagulation 
and endothelial dysfunction. These abnormalities significantly increase the risk of developing atherosclerotic 
complications including stroke and MI, and has been associated with two to three-fold increase in CV mortality6. 
There are evidences where pioglitazone can modify these IR-mediated CV risk factors7,8, thereby exerting cardi-
oprotective action9. In line with these observations, PPARγ are reported to reduce the plasma concentration of 
triglycerides (TGs) by increasing lipid accumulation in the adipose tissue. This effect decreases cardiac fatty acid 
uptake and oxidation, while increasing oxidative phosphorylation of glucose and lactate and therefore, provides 
CV safety by improving cardiac contractility10,11. In addition, compared with some AD agents, namely, sulfony-
lureas and insulin therapy, the use of pioglitazone either alone or in combination is associated with a lower risk 
of hypoglycaemia, a major risk factor for CV events12. Moreover, pioglitazone exert favourable effects in patients 
with nonalcoholic steatohepatitis13.
Despite these advantages, a host of adverse events, primarily body weight (BW) gain, peripheral oedema and 
congestive heart failure as well as controversy with the risk of bladder cancer has limit the use of pioglitazone in 
routine clinical practice. Thus, given its unique insulin sensitising effect, a risk-benefit analysis of pioglitazone 
treatment in patients with T2DM is crucial for determining its place in the current and future glucose-lowering 
treatment algorithm. This is particularly relevant given the current recommendation of individualisation of ther-
apy in patients with T2DM, according to clinical and patient factors14. Therefore, we aimed to conduct a system-
atic review and meta-analysis comparing pioglitazone treatment as monotherapy with other AD monotherapies 
to confirm its efficacy and safety in T2DM patients.
Methods
Search strategy and selection criteria. This systematic review and meta-analysis was developed 
according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement15 
(Supplementary Table S1) with a predefined protocol registered under International Prospective Register of 
Systematic Reviews (PROSPERO) (identification number CRD42018088073). To identify relevant studies, seven 
electronic databases including Web of Science, Medline through PubMed, Embase, Scopus, Cochrane database 
(Cochrane Central Register of Controlled Trials), ClinicalTrials.gov and ScienceDirect were searched with-
out restricting language and publication year up to May 30, 2018. During the electronic search, two themes of 
Medical Subject Headings (MeSH) terms (pioglitazone and diabetes) and related keywords were included, which 
were further combined with Boolean operators (‘AND’ and ‘OR’) using ‘Advanced’ and ‘Expert’ search options. 
The detailed search strategies for different databases are provided (Supplementary Text S1). Reviews, system-
atic reviews, meta-analysis, case reports, editorials, letters, erratum, comments, in vivo and in vitro studies were 
excluded. Duplicate records of electronic databases were removed by using the EndNote software (version X7.7). 
Two investigators (F.A. and M.A.I.) independently screened the titles and abstracts of the identified records. Full-
text of relevant studies were retrieved to independently assess their compliance with the inclusion criteria. Any 
disagreements were resolved by consensus with a third investigator (I.I.). If full-text of relevant studies were una-
vailable online, either the corresponding authors or the first authors of those studies were contacted. Additionally, 
the reference lists of eligible publications were manually checked to find out the studies of interest.
Studies were regarded as eligible for inclusion if (1) they were randomised controlled trials (RCTs) conducted 
on T2DM subjects with no reporting of comorbid diseases or diabetes-associated complications, (2) they com-
pared pioglitazone monotherapy with monotherapies of other FDA approved oral AD drugs, (3) the treatment 
duration was ≥12 weeks, (4) at least reported treatment effects on glycated haemoglobin (HbA1c) level, and (5) 
there was no prior history of T2DM patients treated with any AD drugs or discontinued monotherapy or combi-
nation therapy of AD drugs before starting the trials with or without washout period.
RCTs which compared pioglitazone monotherapy with injectable AD drugs or diet or exercise and also com-
pared with AD drugs which have been discontinued (e.g. troglitazone) or debated (e.g. rosiglitazone) or under 
development (e.g. rivoglitazone) for T2DM treatment were excluded. RCTs where additional AD drugs were 
added as open-label rescue therapy in any treatment group during the trial period were excluded. In addition, 
duplicate publications representing subgroup analysis from the original publication as well as studies where over-
lapping of identical study subjects were observed with other included studies from similar research group were 
also excluded.
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Data extraction and quality assessment. Two investigators (F.A. and M.A.I.) independently extracted 
the data for all analyses. The following features were extracted from each study: first author and year (study ID), 
study location, trial type (multicentre or single centre), trial duration, sample size (males and females), compar-
ator drugs name, HbA1c and fasting blood sugar (FBS) levels during enrolment, maintenance of lifestyle inter-
vention during trials, number of patients (males and females) taking pioglitazone and comparator drugs along 
with their age, duration of diabetes and daily dose of drugs. Extracted information were then compared and any 
discrepancies such as unclear or missing data presentation were resolved by a consensus. If unresolved, requests 
for information were sent to corresponding or first authors of the respective studies for further clarifications.
To assess treatment efficacy, the mean change in HbA1c from baseline to study end was considered as the pri-
mary outcome. Depending on the reports of the selected studies, the mean changes in FBS, BW and homeostasis 
model assessment-insulin resistance (HOMA-IR) from baseline were considered as secondary outcomes. On the 
other hand, the change in blood pressure (BP) [systolic blood pressure (SBP) and diastolic blood pressure (DBP)], 
lipid parameters [low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TC) and TGs] 
and records of adverse events were analyzed as safety outcomes. Predefined subgroup analyses were performed 
for the primary (changes in HbA1c) and secondary (changes in FBS) glycaemic outcomes based on specific com-
parator drugs, geographical location, trial duration, diabetes duration and pioglitazone dosage.
Heterogeneity of treatment effects between trials was assessed by using the χ² test (p < 0·10 indicates signif-
icant heterogeneity) and I²-statistic (degree of heterogeneity). The following thresholds of I2-statistic was con-
sidered to interpret heterogeneity: 0–25% (low heterogeneity), 26–75% (moderate heterogeneity) and 76–100% 
(substantial heterogeneity)16. If moderate or substantial heterogeneity was observed, we planned to perform sen-
sitivity analyses for primary and secondary glycaemic outcomes to explore potential sources of heterogeneity 
excluding studies with overall high risk of bias (poor quality studies), open-label studies, multicentre studies and 
studies presented data in adjusted mean difference. We also planned to construct Galbraith plot if the source of 
heterogeneity remained unidentified after sensitivity analyses.
The methodological quality of each study was assessed by Cochrane Collaboration risk of bias tool17 based on 
the following criteria: random sequence generation, allocation concealment, blinding of participants and personnel, 
blinding of outcome assessment, incomplete outcome data and selective reporting. For each study, the overall risk of 
bias was regarded as high in the presence of high risk in any domain, low if all key domains (except random sequence 
generation and allocation concealment domain) were of low risk, and unclear in all other cases18. Publication bias was 
investigated via visual inspection of contour-enhanced funnel plot for primary and secondary glycaemic outcomes. 
Additionally, Begg’s and Egger’s tests were performed for quantitative publication bias analysis (p < 0.05 was considered 
significant)19. Results of publication bias were further validated by constructing trim and fill funnel plot.
For efficacy and safety measures, the mean differences in HbA1c, FPG, BW, HOMA-IR, SBP, DBP, LDL, HDL, 
TC and TG were calculated with standard deviations (SDs). They were assessed as continuous variables using 
weighted mean differences (WMD) and 95% confidence interval (CI). Study results which reported in standard 
error or 95% CI were converted into SDs. Safety measures reported as adverse events were assessed as dichoto-
mous variables using risk ratio (RR) with 95% CI. Random-effects model was used for the meta-analyses. The 
results were considered statistically significant when p < 0.05. The forest plots were generated using the Review 
Manager (RevMan, version 5.3) software20. Illustration of Galbraith plot, funnel plots, and Begg’s and Egger’s tests 
were constructed in metafor package with R (version 3.4.1) and RStudio (version 1.0.153) software.
Results
Selection and inclusion of studies. Based on the database search, a total of 7,612 articles were retrieved, 
from which 18 met the inclusion criteria21–38. Two studies were excluded as required data for meta-analyses 
couldn’t retrieved (Supplementary Text S2). The remaining 16 studies comprising 2,681 participants (1,503 males 
and 1,178 females, published between 2002 and 2017) were included in the meta-analyses. A flow chart of study 
selection process is illustrated in Fig. 1.
Characteristics of included studies. Table 1 summarizes the major characteristics of the included studies. 
Most studies were conducted in Asia (six)22–27, followed by Europe (four)21,28,29,31, multinational (four)32,33,35,36 and 
North America (two)30,34. Only five studies were conducted for a minimum 12 weeks’ duration21,24,25,35,36. Nine 
out of 16 studies were multicentre. Mean age of participants randomised to pioglitazone and comparator drugs 
ranged from 45.1 ± 8.5 to 64.1 ± 8.5 years and 44.4 ± 10.6 to 65.1 ± 7.7 years, respectively. Five studies were con-
ducted solely on naïve T2DM patients21–24,27, while in other studies, the mean diabetes duration of participants 
ranged from 2.2 ± 3.3 to 6.5 ± 4.7 years (pioglitazone) and 1.9 ± 3.1 to 6.4 ± 3.8 years (comparators). Pioglitazone 
was compared with metformin in six studies21–24,26,27, followed by sulfonylureas (SUs) in five studies25,27,28,31,34, 
dipeptidyl peptidase (DPP)-4 inhibitors in four studies32,33,35,36, α-glucosidase inhibitor (acarbose) in one study29 
and meglitinide (repaglinide) in one study30. Among all studies, only one study compared pioglitazone to both 
metformin and a SU drug27.
Risk of bias of the included studies. Risk of bias assessment of the included studies were summarized 
in Fig. 2. Random sequence generation and allocation concealment were described adequately in eight22–26,29,34,36 
and four26,29,34,36 of the 16 included studies, respectively. Seven studies were conducted as double-blinded28,31–36, 
1421–26,28,29,31–36 studies reported the number of patients lost to follow-up while five28,29,31–33 studies mentioned the 
outcomes of interest in a pre-specified way. The overall risk of bias was low in four28,31–33, unclear in three21,35,36 
and high in the remaining studies.
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Main results. Analysis of primary outcome. In primary outcome analysis of 16 studies, pioglitazone mon-
otherapy reduced HbA1c by 0.05% with no significant difference (95% CI: −0.21 to 0.11, p = 0.56) and with 
substantial amount of heterogeneity (I2 = 81%, p < 0.00001) (Fig. 3).
Analyses of secondary outcomes. From secondary outcomes analyses, the effect of pioglitazone treatment was 
observed to be associated with decreased FBS level significantly by 0.24 mmol/l (95% CI: −0.48 to −0.01, p = 0.04) 
from the baseline with moderate heterogeneity (I2 = 65%, p < 0.0001) compared to the comparator AD drugs 
(Fig. 3), and associated with increased BW (WMD: 2.06, 95% CI: 1.11 to 3.01, p < 0.0001) without substantial het-
erogeneity (Supplementary Fig. S1). Both pioglitazone and comparator groups had similar effect on HOMA-IR 
(WMD: 0.05, 95% CI: −0.49 to 0.59, p = 0.86), associated with substantial heterogeneity (Supplementary Fig. S1).
Subgroup analyses. From subgroup analysis with specific comparator drugs, pioglitazone reduced HbA1c by 
0.12% more than metformin (95% CI: −0.52 to 0.28, p = 0.57) and showed similar efficacy as SUs (WMD: −0.02, 
95% CI: −0.24 to 0.21, p = 0.89) and DPP-4 inhibitors (WMD: 0.01, 95% CI: −0.19 to 0.20, p = 0.94). Though a 
significantly greater reduction by 0.68% in HbA1c was achieved with pioglitazone (WMD: −0.68, 95% CI: −1.13 
to −0.23, p = 0.003) compared to acarbose, pioglitazone functioned less effectively than repaglinide (WMD: 0.50, 
95% CI: 0.04 to 0.96, p = 0.03). In case of FBS reduction, pioglitazone was significantly more efficacious than 
DDP-4 inhibitors (WMD: −0.38, 95% CI: −0.70 to −0.06, p = 0.02) and acarbose (WMD: −1.80, 95% CI: −2.74 
to −0.86, p = 0.0002), and also showed better efficacy than metformin and SUs, although the results were insig-
nificant (Supplementary Fig. S2). Based on geographical location, HbA1c reduction by pioglitazone was more 
efficacious in European studies, followed by Asian and North American studies but pioglitazone was similarly 
efficacious as comparators in multinational studies, although the difference was not statistically significant in 
any of the groups. Based on the FBS analysis, efficacy of pioglitazone was statistically significant in decreasing 
FBS level in multinational studies (WMD: −0.38, 95% CI: −0.70 to −0.06, p = 0.02), followed by non-significant 
reduction in European, North American and Asian studies (Supplementary Fig. S3). Analysis of studies follow-
ing trial duration revealed that patients receiving pioglitazone monotherapy had more HbA1c reduction than 
those receiving monotherapy of comparators when the treatment was prescribed for >12 weeks (WMD: −0.13, 
95% CI: −0.31 to 0.05, p = 0.16). A similar scenario was observed with FBS where there was significant FBS 
reduction (WMD: −0.49, 95% CI: −0.92 to −0.05, p = 0.03) (Supplementary Fig. S4). In naïve T2DM patients, 
pioglitazone improved the glycaemic status by decreasing 0.16% of HbA1c level (95% CI: −0.61 to 0.28, p = 0.47) 
more than the comparators, whereas there was similar efficacy to comparators in patients with diabetes for long 
term (WMD: −0.02, 95% CI: −0.18 to 0.15, p = 0.85). In contrast, pioglitazone yielded significantly greater 
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3,576 articles were excluded based on the 
following criteria 
1. Non-human subjects (n=677)
2. Review articles and meta-analysis (n=1,086)
3. Case reports and erratum (n=126)
4. Editorials, letters and comments (n=290)
5. Duplicate studies (n=1,397)
4,036 articles were selected for title and abstract 
evaluation
16 studies were selected for the meta-analysis
4,018 articles were excluded as those did not 
comply with the study inclusion criteria
18 articles were selected for quantitative evaluation
PubMed
n=3,166
Web of Science
n=1,365
Scopus
n=898
Cochrane Database
n=634
Total
n=7,612
ScienceDirect
n=297
ClinicalTrials.gov
n=81
Embase
n=1,171
2 articles were excluded due to unusable data 
presentation
Figure 1. Flow chart of study selection process.
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reduction of FBS (WMD: −0.49, 95% CI: −0.84 to −0.13, p = 0.007) in long term T2DM patients as compared to 
naïve patients (Supplementary Fig. S5). Comparison between pioglitazone dosage showed that 30 mg fixed-dose 
was similarly efficacious as the comparators (WMD: −0.01, 95% CI: −0.29 to 0.28, p = 0.96), whereas 45 mg 
fixed-dose showed a trend towards greater HbA1c reduction compared with other AD drugs (WMD: −0.48, 
95% CI: −1.04 to 0.07, p = 0.09). Studies prescribing variable-dose of pioglitazone in an increasing level from 
low to moderate/high dose reported 0.14% less reduction in HbA1c than the comparators (95% CI: 0.11 to 0.18, 
p < 0.00001). In case of FBS reduction, the efficacy of pioglitazone 45 mg fixed-dose was significantly greater 
(WMD: −2.04, 95% CI: −2.86 to −1.21, p < 0.00001), followed by 30 mg fixed-dose and variable dose (15–45 mg) 
than comparators (Supplementary Fig. S6).
Sensitivity analyses. From sensitivity analyses, removal of multicentre (Supplementary Fig. S7), open-label 
(Supplementary Fig. S8), high risk of bias (Supplementary Fig. S9) and adjusted mean data presenting studies 
(Supplementary Fig. S10) from HbA1c and FBS main analyses failed to identify the responsible sources for sub-
stantial and moderate heterogeneity, respectively. Further investigation of HbA1c result with Galbraith plot was 
No Study ID
Study 
location, 
type
Study 
duration
Sample  
size (male/
female)
Sample size (male/
female)
Name of  
CPRs
Duration of diabetes 
(mean ± SD) Age in years (mean ± SD) Daily dose (mg/day)
HbA1c/FBS  
value during  
enrolment
Maintenance of  
lifestyle  
intervention  
during trials  
(YES/NO/NR)PIO CPRs PIO CPRs PIO CPRs PIO CPRs
1 Mori2017
Japan,
MC 3 m
58
(24/34) 29 (13/16)
29
(11/18) Metformin NR NR 64.1 ± 8.5 65.1 ± 7.7
30 for male 
and 15 for 
female
750 NR/NR NR
2
Esteghamati
2015a* Iran,
SC 12 w
88
(39/49)
46
(23/23)
42
(16/26) Metformin NDD NDD
49.5 ± 2.0 49.4 ± 2.1
30 1000 NR/NR NR
Esteghamati
2015b* 53.5 ± 1.6 49.0 ± 1.7
3 Esteghamati2014a**
Iran,
SC 3 m
81
(47/34)
42
(14/28)
39
(20/19) Metformin NDD NDD 51.3 ± 7.9 50.0 ± 9.1 30 1000 ≥6.5%/7.0 mmol/L NR
4 Esteghamati2014b**
Iran,
SC 3 m
82
(36/46)
42
(19/23)
40
(17/23) Metformin NDD NDD 51.8 ± 1.3 49.4 ± 1.3 30 1000 NR/NR NR
5 Alba 2013
Mixed  
nations,  
MC
12 w 106(51/55)
54
(23/31)
52
(28/24) Sitagliptin 2.4 ± 1.4 y 2.4 ± 1.6 y 53.4 ± 7.8 54.6 ± 7.6 30 100
≥7–≤10%  
(drug naïve or  
≥6.5–≤9% on  
treatment/≥7.2–\ 
≤14.4 mmol/L
NR
6
Pérez- 
Monteverde  
2011
Mixed  
nations,  
MC
12 w 492(300/192)
248
(148/100)
244
(152/92) Sitagliptin 3.5 ± 3.7 y 2.9 ± 2.8 y 51.7 ± 10.1 50.5 ± 10.9 15–30 100
≥7.5–≤12% />7.2– 
<17.8 mmol/L NR
7 Hu2010
China,
SC 12 w
90
(45/45)
44
(21/23)
46
(24/22)
Glimepiride 
or gliclazide 6.5 ± 4.7 y 6.4 ± 3.8 y 52.6 ± 9.4 52.0 ± 9.1
15–45 
(mean 
dose 25)
2–6 (mean 
dose 4) or 
80–240 
(mean dose 
120)
≥7.0%/7.0 
–13.0 mmol/L NR
8 Rosenstock2010
Mixed  
nations,  
MC
26 w 327(166/161)
163
(90/73)
164
(76/88) Alogliptin
3.20 ±  
3.74 y
3.23 ±  
3.56 y 51.5 ± 10.7 52.6 ± 10.4 30 25 7.5–11%/NR NR
9 Erdem2008
Turkey,
SC 12 w
44
(18/26)
21
(8/13)
23
(10/13) Metformin NDD NDD 54.9 ± 7.8 55.1 ± 9.9 15–45 1000–2000 NR/NR Yes
10 Cooper2008
UK,
SC 20 w
21
(16/5)
10
(8/2)
11
(8/3)
Gliben-
clamide ~ 2.6 y ~ 2.4 y 56.0 ± 3.7 58.0 ± 2.6 45 5 <9%/NR NR
11 Rosenstock2007
Mixed 
locations,  
MC
24 w 315(201/114)
161
(103/58)
154
(98/56) Vildagliptin 2.2 ± 3.3 y 1.9 ± 3.1 y 52.4 ± 10.3 51.4 ± 10.8 30 100
7.5–11.0%/ 
<15 mmol/L NR
12 Perriello2006
Italy,
MC 12 m
283
(185/98)
146
(97/49)
137
(88/49) Gliclazide 9.8 ± 5.4 y 8.5 ± 4.1 y 58.0 ± 8.0 59.0 ± 7.0
30–45 
(mean 
dose 40)
80–320 
(mean dose 
84)
>7.5%/NR NR
13
Rama- 
chandran 
2004a*** India,
SC 14 w
62
(46/16) 23 (17/6)
21
(15/6) Metformin
NDD
NDD
45.1 ± 8.5
44.4 ± 10.6
15–30
250–850
8.5–11.0%/NR Yes
Rama- 
chandran 
2004b***
18
(14/4) Glimepiride NDD 45.3 ± 10.3 1–2
14 Tan2004
Mexico,
MC 52 w
244
(119/125)
121
(54/67)
123
(65/58) Glimepiride
77.8 ±  
79.2 m
81.2 ±  
82.8 m 55.1 ± 8.0 55.7 ± 9.3
15–45
(mean 
dose 37)
2–8
(mean 
dose 6)
>7.5%– 
≤11% / NR Yes
15 Jovanovic2004
USA,
MC 24 w
123
(67/56)
62
(31/31)
61
(36/25) Repaglinide
6.1 ±  
3.9 y
6.9 ± 
 6.0 y 56.2 ± 12.2 57.8 ± 13.1 30 10
>7.0%– 
<12%/NR NR
16 Göke2002
Germany,  
MC 26 w
265
(143/122)
129
(69/60)
136
(74/62) Acarbose
57.0 ±  
55.4 m
59.1 ±  
50.3 m 58.9 ± 9.1 58.8 ± 9.1 45 300
7.5–11.5%/ 
≥7.8 mmol/L Yes
Table 1. Major characteristics of the included studies. MS: Multicentre, SC: Single centre, NDD: newly 
diagnosed diabetes, NR: not reported, PIO: pioglitazone, CPRs: comparators, SD: standard deviation, m: 
months, w- weeks, y: years. *Esteghamati 2015a and Esteghamati 2015b is same study, as results are divided into 
male and female patients, thus Esteghamati 2015a represents results of male patients and Esteghamati 2015b 
represents results of female patients. **Esteghamati 2014a and Esteghamati 2014b are different studies but 
published in the same year. ***Ramachandran 2004a and Ramachandran 2004a is the same study, as PIO was 
compared with two different antidiabetic drugs, thus Ramachandran 2004a represents PIO vs metformin and 
Ramachandran 2004b represents PIO vs glimepiride.
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also unsuccessful whereas Galbraith plot construction following FBS findings identified two potential included 
studies28,29 as contributors for moderate heterogeneity (Fig. 4).
Publication bias assessment. Visual inspection of contour-enhanced funnel plots for HbA1c and FBS analyses 
showed no evidence of publication bias which were quantitatively validated by Begg’s (p = 1.00 and p = 0.65) and 
Egger’s tests (p = 0.45 and p = 0.43), respectively (Fig. 5). Further verification by trim and fill funnel plots showed 
no evidence of missing studies, thereby confirming the absence of publication bias (Fig. 6).
Figure 2. Risk of bias summary. Presentation of the risk of bias summary of the review author’s judgments 
about each risk of bias item for each included study. Studies in green or + are at low risk of bias.
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Analyses of safety outcomes. From safety outcomes analyses, improvements in BP was non-significantly greater 
(1.05 mmHg) in pioglitazone-treated patients than the comparators (95% CI: −4.29 to 2.19, p = 0.52). Among the 
lipid parameters, pioglitazone decreased TGs level by 0.71 mmol/l (95% CI: −1.70 to 0.28, p = 0.16) but couldn’t 
reduce the LDL and TC level as significantly as reduced by other comparative treatments. On the other hand, 
both groups exerted similar efficacy in increasing baseline HDL level without statistically significant difference 
(Supplementary Fig. S11). Among the reported adverse events, pioglitazone as initial monotherapy was not sig-
nificantly associated with the risk of hypoglycaemia incidence (RR: 0.51, 95% CI: 0.33 to 0.80, p = 0.003), but 
significantly associated with risk of causing peripheral oedema in T2DM patients (RR: 2.21, 95% CI: 1.48 to 
3.31, p = 0.0001) compared to the comparative monotherapy drugs. Besides, neither pioglitazone nor comparator 
drugs significantly contributed in developing upper respiratory tract infections (naspharingitis and sinusitis), 
nervous system disorders (headache, dizziness, syncope, cerebral ischaemia), musculoskeletal and connective 
tissue disorders (anthralgia, back pain, musculoskeletal pain), vascular disorders (arterial thrombosis and aortic 
stenosis), cardiovascular events, diarrhea, asthenia, abnormal liver functions, vomiting, nausea, colon cancer, 
breast cancer and non-cardiac chest pain (Supplementary Fig. S12). Interestingly, no incidence of bladder cancer 
was reported due to pioglitazone treatment.
(a)
(b)
Figure 3. Forest plots showing effects of pioglitazone monotherapy versus comparator monotherapy on the 
primary (change in HbA1c) and secondary (change in FBS) glycaemic outcomes. Weighted mean difference in 
change from baseline in HbA1c (a) and FBS (b).
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Discussion
Due to variations in mechanisms and sites of action, all existing AD drugs possess comparative differences in 
their glucose lowering efficacy. In our meta-analysis, pioglitazone monotherapy produced similar efficacy as other 
AD drugs in HbA1c reduction but greater efficacy with statistical significance in FBS reduction. Subgroup analy-
sis with specific comparator drugs revealed pioglitazone to be a good choice of treatment in reducing HbA1c and 
FBS which was not inferior than metformin, SUs and DPP-4 inhibitors. This findings are supported by several 
(a) (b)
Source of heterogeneity
Figure 4. Galbraith plots illustrating the source of heterogeneity among included studies in HbA1c (a) and FBS 
(b) outcomes.
(a)
(b)
Figure 5. Contour-enhanced funnel plots of the included studies showing no evidence of publication bias in 
HbA1c (a) and FBS (b) outcomes.
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previously published reports on patients with T2DM39–44. However, as only one study each comparing pioglita-
zone vs acarbose and pioglitazone vs repaglinide lead to opposite findings, it is difficult to judge which mono-
therapy was more efficacious. Subgroup analysis on geographical locations showed variable glycaemic response 
of T2DM patients with pioglitazone treatment, indicating variable drug response due to patients’ ethnic differ-
ence, age, sex, baseline weight and HbA1c45. Comparing studies in terms of duration of diabetes revealed a more 
pronounced efficacy of pioglitazone on FBS reduction in patients’ having long-term T2DM than in naïve T2DM 
patients’. It is plausible that prior AD treatment of a portion of patients before enrollment might have influenced 
the efficacy of pioglitazone. However, this scenario was not observed in the context of HbA1c reduction, therefore 
warranting further investigations. In subgroup analysis following trial duration, pioglitazone was efficacious in 
reducing HbA1c and FBS levels than comparators when the trials were conducted for >12 weeks duration sug-
gesting a slower onset action of pioglitazone to give maximal effect. A few long-term (52-week) studies evaluating 
pioglitazone monotherapy also supported the sustained antihyperglycaemic effect of pioglitazone34,44. Subgroup 
analysis based on dosage revealed a higher efficacy of fixed-dose pioglitazone in improving glycaemic response 
than variable-dose which again suggests the gradual increase in therapeutic action by pioglitazone when given at 
a fixed-dose than in variable-dose.
In line with earlier findings in T2DM patients39,46, we also observed significant mean increase in patients’ BW 
(2.06 kg) following pioglitazone use. It is believed that increased BW with pioglitazone is due to fluid retention 
and fat accumulation in the body. Although previous studies reported BW gain in a higher rate, a few but con-
tradictory findings exist where the use of pioglitazone without or with lower BW gain were also reported5,41,47. 
Nonetheless, BW gain is a major problem among pioglitazone users, which may limit its utility. However, numer-
ous studies have shown the benefits of adjuvant strict dietary restriction with exercise intervention to attenuate 
pioglitazone-induced BW gain48–50.
The HOMA-IR method is widely used for assessing insulin resistance in clinical trials and epidemiological 
studies, improvement of which indicates enhanced insulin sensitivity. Since pioglitazone is an insulin sensitiser 
which improves insulin sensitivity by acting on peripheral and liver cells; it is anticipated that pioglitazone would 
(a)
(b)
Figure 6. Trim and fill funnel plots showing absence of missing studies and verifying no evidence of 
publication bias in HbA1c (a) and FBS (b) outcomes.
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improve HOMA-IR compared with comparator37,51. In this meta-analysis however, pioglitazone had similar effi-
cacy as comparators on HOMA-IR. However, interestingly detailed analysis of individual studies revealed that 
studies (n = 3) conducted in Iran22–24 appear to favour the comparators rather than pioglitazone indicating the 
possible influence of genetic makeup in the pharmacodynamics of pioglitazone. Apart from the Iranian studies, 
other studies (n = 7) favoured pioglitazone with statistical significance (p = 0.05).
Consistent with previous observations, this meta-analysis confirmed the positive influence of pioglitazone on 
the lipid profile of T2DM patients with significant decrease in TGs and increase in HDL (although mean HDL 
increase was similar to comparators)43,44,51–55. Several studies have reported the effect of pioglitazone in increasing 
TC and LDL43,44,54,55, but pioglitazone appeared to be associated with TC and LDL reduction in this meta-analysis 
which was also supported by other evidences51–53. It is plausible that variations in treatment duration, piogli-
tazone dosage as well as patients’ compliance to pioglitazone are responsible for the contradictory findings of 
individual studies. Large number of clinical studies have reported pioglitazone as a good regulator of BP53,55. Our 
meta-analysis results also support the contribution of pioglitazone in reducing BP, particularly SBP, in patients 
with T2DM, although changes in BP from baseline were not significantly associated with pioglitazone use. Since 
hypertension is frequently diagnosed as a co-morbidity in patients with T2DM which could lead to long-term 
vascular and renal complications, BP-lowering efficacy of pioglitazone may be helpful in preventing the develop-
ment of hypertension and its associated complications in T2DM patients.
Similar to prior studies44,54, the incidences of oedema were significantly higher with pioglitazone, while the 
incidences of hypoglycaemia were significantly lower than comparators. Although limited number of studies 
were included in these analyses, the presence of low heterogeneity indicates reliability of the results. The low 
hypoglycaemic risk associated with pioglitazone monotherapy was reported to be beneficial for T2DM patients 
with CV disease, especially in preventing mortality after severe hypoglycaemia56. Two meta-analyses investigated 
the association of pioglitazone with CV risk reported pioglitazone with no relevant effect on CV events among a 
diverse population of diabetes patients, significantly lower risk of death and reduced all-cause mortality, thereby 
further supporting our meta-analysis results57,58. Despite the favourable effect, pioglitazone treatment in patients 
with underlying heart disease may be harmful since pioglitazone-mediated peripheral oedema can progress into 
congestive heart failure. Apart from the aforementioned adverse events, analysis of other reported adverse events 
during pioglitazone treatment did not reach statistical significance due to insufficient included studies and there-
fore, these results were not able to evaluate the safety profile of pioglitazone. However, the incidence of bladder 
cancer during pioglitazone treatment was not reported in any of the included studies supporting the conclusion 
of a recent meta-analysis59 which suggested that other factors but not pioglitazone may contribute to the risk of 
bladder cancer.
Although a substantial and moderate amount of heterogeneity was noted in both HbA1c and FBS analyses 
respectively, sensitivity analyses could not explain the sources of heterogeneity based on the quantitative analysis 
(I2). Therefore, none of the factors analysed for sensitivity contributed to the heterogeneity. Even by using the 
Galbraith plot, responsible studies causing the substantial heterogeneity in HbA1c analysis were unidentified. 
However, the unidentified source of heterogeneity could potentially be attributed to variation among included 
trials regarding ethnicity of participants, dosing of comparators in the control group, types of diet and exercise 
maintained along with AD drugs, patients’ baseline characteristics such as baseline HbA1c and varying use of AD 
drugs before randomisation. We could not explore the influence of these factors through sensitivity analyses due 
to lack of relevant data. On the other hand, Galbraith plot revealed two contributing studies28,29 for the heteroge-
neity of FBS results. Since both studies utilised pioglitazone 45 mg fixed-dose and caused greater reduction of FBS 
from baseline than other studies, it is plausible that this factor is the source of heterogeneity.
This systematic review and meta-analysis has several notable strengths. First, to the best of our knowledge, 
it is the first systematic review and meta-analysis assessing the efficacy and safety of pioglitazone monotherapy 
against monotherapy of other AD drugs for treating patients with T2DM. Second, a comprehensive and robust 
literature search without year and language restriction were conducted across seven electronic databases follow-
ing a standard methodology. Third, our inclusion criteria ensured that only FDA approved AD drugs currently 
in use in clinical practice were included for the analysis. We accepted only RCTs conducted for at least 12 weeks’ 
duration so that HbA1c test during the follow-up reflects the treatment efficacy on the average glucose levels of 
the previous three months. Fourth, no publication bias was observed from both visual (contour-enhanced funnel 
plot) and quantitative analyses (Begg’s and Egger’s tests). Additionally, the absence of missing studies from trim 
and fill funnel plot analysis further confirms that we were unlikely to have missed studies that could have altered 
the meta-analysis findings. Fifth, five different subgroup analyses have been conducted to find out the possible 
factors contributing to the efficacy of pioglitazone monotherapy on HbA1c reduction comparing to other drugs.
Despite these strengths, we do acknowledge certain limitations. First, the result of this meta-analysis is rep-
resented by a small sample size (n = 2,681) from only 16 RCTs. Second, we had to exclude two potential studies 
due to lack of data representation. We couldn’t retrieve the required information even after requesting the corre-
sponding and first authors of those studies. Third, 9 out of 16 studies were judged as high methodological risk in 
overall bias assessment, which was contributed by RCTs with open-label study design and RCTs with reporting 
bias. Fourth, a substantial level of heterogeneity in HbA1c analysis was noted. We couldn’t identify the source of 
heterogeneity even after conducting different types of sensitivity analyses as well as constructing Galbraith plot. 
Fifth, none of the RCTs except one study34 were designed to evaluate the long-term efficacy and safety of piogli-
tazone monotherapy on T2DM patients. Also, a substantial number of studies did not report on adverse events 
possibly because they were not designed to evaluate such endpoint and not endowed with a sufficiently long study 
duration.
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Conclusions
Based on the findings of this meta-analysis, we concluded that pioglitazone monotherapy showed overall favour-
able risk-benefit balance. Specifically, pioglitazone is an effective treatment option in managing T2DM patients 
due to its potential of ameliorating hyperglycaemia, adverse lipid metabolism and BP. Improvement of these CV 
risk factors is crucial in terms of CV protection and stroke prevention in T2DM patients. Pioglitazone mono-
therapy can also be used as an alternative to metformin monotherapy if metformin cannot be tolerated or as a 
combination therapy if metformin alone fails to achieve target HbA1c level. Since hypoglycaemia is recognized 
as a potential cause of death60, particularly due to cerebral damage, the low hypoglycaemic risk of pioglitazone 
over other AD drugs will be advantageous in preventing mortality in T2DM patients. However, development 
of oedema and BW gain due to pioglitazone cannot be ignored. Hence, it is suggested to avoid pioglitazone 
treatment in patients with previously diagnosed heart failure. Since approximately >90% of T2DM patients are 
obese, pioglitazone-mediated BW gain can be ameliorated by lifestyle intervention including nutrition therapy 
and regular physical activity. Patients should be followed-up to monitor BW gain, since sudden, uncontrolled BW 
gain may be an indication of new onset heart failure. As oedema and weight gain is dose-dependent, low-dose of 
pioglitazone which proved as similarly efficacious as standard-dose in improving glucose and lipid metabolism61, 
could possibly be used as an alternative treatment. Additionally, combination of pioglitazone with FDA approved 
anti-obesity drug can be explored on T2DM obese patients. Whether pioglitazone increases the risk of bladder 
cancer in T2DM patients remains unclear, but no signal for this adverse event was observed in the meta-analysis. 
Since pioglitazone is the only insulin sensitiser among existing AD drugs and is the only TZD currently in use, we 
believe that the evidence from this meta-analysis support the ongoing role of pioglitazone in managing patients 
with T2DM. Furthermore, RCTs with pioglitazone monotherapy are suggested for weighing its long-term benefits 
and risks in T2DM patients.
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